Nyrada Inc Cash Flow Conversion Efficiency
Nyrada Inc cash flow conversion efficiency. Based on the latest financial reports, Nyrada Inc (NYR) has a cash flow conversion efficiency ratio of -0.453x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.46 Million ≈ $-3.16 Million USD) by net assets (AU$9.84 Million ≈ $6.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nyrada Inc (2018–2025)
Cash flow conversion efficiency of Nyrada Inc from 2018 to 2025. This chart illustrates how Nyrada Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Nyrada Inc for real-time trading data and today's change.
Nyrada Inc Cash Flow Conversion Ratio Explained
Nyrada Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nyrada Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nyrada Inc ranked by their cash flow conversion efficiency. Also see NYR market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S 11 Group Public Company Limited
BK:S11
|
0.020x |
|
Escar Turizm Tasimacilik Ticaret AS
IS:ESCAR
|
0.012x |
|
Demco Public Company Limited
BK:DEMCO
|
-0.004x |
|
Pylon Public Company Limited
BK:PYLON
|
0.022x |
|
Immutep Ltd ADR
NASDAQ:IMMP
|
-0.284x |
|
Phenixfin Corporation
NASDAQ:PFX
|
0.000x |
|
Novogenia AG
XETRA:7V0
|
N/A |
|
Nova Minerals Limited
NYSE MKT:NVA
|
0.066x |
Annual Cash Flow Conversion Efficiency for Nyrada Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nyrada Inc from 2018 to 2025. Review Nyrada Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$3.58 Million ≈ $2.53 Million |
AU$-5.05 Million ≈ $-3.57 Million |
-1.412x | -831.05% |
| 2024-06-30 | AU$5.05 Million ≈ $3.57 Million |
AU$-766.29K ≈ $-542.20K |
-0.152x | +91.07% |
| 2023-06-30 | AU$4.26 Million ≈ $3.01 Million |
AU$-7.23 Million ≈ $-5.12 Million |
-1.698x | -565.58% |
| 2022-06-30 | AU$11.50 Million ≈ $8.14 Million |
AU$-2.93 Million ≈ $-2.08 Million |
-0.255x | -33.34% |
| 2021-06-30 | AU$14.49 Million ≈ $10.25 Million |
AU$-2.77 Million ≈ $-1.96 Million |
-0.191x | +76.02% |
| 2020-06-30 | AU$5.53 Million ≈ $3.91 Million |
AU$-4.41 Million ≈ $-3.12 Million |
-0.798x | -297.19% |
| 2019-06-30 | AU$-4.95 Million ≈ $-3.51 Million |
AU$-2.01 Million ≈ $-1.42 Million |
0.405x | -20.09% |
| 2018-06-30 | AU$-1.36 Million ≈ $-964.18K |
AU$-690.18K ≈ $-488.35K |
0.506x | -- |
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more